You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Systematic Medical Approach to Reward Transformation SMART for Brain Health in Opioid Use Disorder

    SBC: Versa Integrated Solutions, Inc.            Topic: 102

    Summary In recent years opioid use disorder OUD and deaths due to opiate overdose e g with heroin fentanyl oxycodone in suburban and rural non minority groups has created an urgency for approaches to stem this epidemic but the rise in OUD and opiate overdose deaths has occurred in inner cities at similar rates Heroin misuse and addiction are persistent problems in African American commu ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Biocatalytic production of precursors to lutein and zeaxanthin to address age related macular degeneration

    SBC: EscaZyme Biochemicals, LLC            Topic: N

    Project Summary Atrophic dry age related macular degeneration AMD is the leading cause of severe loss of vision for those over age Dietary supplements containing lutein and zeaxanthin are recommended by the NEI for those at risk of late AMD There has been a corresponding growth in demand for these two xanthophylls Lutein and zeaxanthin are currently sourced from marigolds grown mostl ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Recombinant High Affinity Long and Dual Acting Equine CG Analogs for Improved and More Ethical Reproduction in Pigs and Cattle

    SBC: TROPHOGEN INC            Topic: NICHD

    As their first application for veterinary health the two PI s have already remarkably employed their novel patented superagonist and neoglycosylation technology to develop the first recombinant much more potent and long acting bovine FSH antagonists for improved cattle reproduction and a potential $ Million annual market This work was supported by a previous phase SBIR from FDA CVM whic ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Therapies for Duchenne Muscular Dystrophy

    SBC: MYOLOGICA, LLC            Topic: NIAMS

    Project Summary Myologica is a small business focused on developing therapeutics for neuromuscular diseases Started in collaboration with the University of Maryland Myologica maintains a vigorous in house pre clinical discovery program in Duchenne Muscular Dystrophy DMD while providing consultation and specialized neuromuscular function testing for non profit and corporate clients The object ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Cellular Immunotherapy for SSc

    SBC: CELDARA MEDICAL, LLC            Topic: NIAMS

    Project Summary Systemic sclerosis SSc is a systemic autoimmune disease that results in widespread fibrosis of the skin and internal organs vascular dropout and autoantibody formation SSc has the highest case fatality rate of any systemic autoimmune disease and there remain for FDA approved therapies Analysis of gene expression data on samples collected from SSc patients strongly indicates th ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Laser Speckle Imaging Chip for Telehealth Applications

    SBC: VASOPTIC MEDICAL, INC.            Topic: NIA

    ABSTRACT The availability of improved diagnostic tools in the primary care environment capable of diagnosing diseases in their earliest stages could significantly improve disease managementPrimary beneficiaries would be the elderlywho are at increased risk for a number of progressively debilitating diseasesbut who may face practical cost and convenience hurdles in routinely presenting to specialis ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Development and Commercialization of Predictive Biomarker Panel and In Office Kit for the Management of Diabetic Macular Edema

    SBC: OCULAR PROTEOMICS, LLC            Topic: N

    Abstract Diabetic Macular Edema DME is a vision threatening stage in Diabetic Retinopathy DR that can result in legal blindness The biochemical mechanisms that drive DME progression are not well understood and treatments address only portions of the disease pathology The available treatment options vary widely from injectable anti VEGF to injectable steroids to laser treatments and carry a ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Inhibitors of PSMB and PSMB for the Treatment of Multiple Myeloma

    SBC: InhiProt            Topic: 103

    Multiple myeloma is incurable hematologic malignancy with an expected median survival of years The proteasome inhibitors bortezomib carfilzomib and the recently approved ixazomib are a mainstay of current myeloma treatment Despite an initial response rate approaching to proteasome inhibitor containing combinations all patients relapse and eventually become resistant to any treatments ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia

    SBC: AAVOGEN INC            Topic: 102

    PROJECT SUMMARY. The skeletal muscle wasting that occurs with cancer cachexia compromises quality of life and is both directly and indirectly responsible for cancer mortalities. Tumor-derived and tumor-responsive factors as well as many therapeutics themselves contribute to the cachectic state, although nutritional support has little if any positive effect on restoring striated muscle mass or func ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Development of PEGylated MTI for the treatment of relapsed Myeloma

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    ABSTRACT Modulation Therapeutics is developing a first in class cyclic peptide coined MTI for the treatment of multiple myeloma The company currently has a license for the parent molecule which has been awarded a patent covering the intellectual property for both composition of matter and use in cancer in the US and Europe Modulation Therapeutics is now poised to further advance this class ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government